← All trials
NCT04895449
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 16, 2021
- Primary completion
- Mar 1, 2022
- Completion date
- Mar 1, 2022
- First posted
- May 20, 2021
- Last posted
- Nov 30, 2021
- Enrollment
- 60
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of HamburgLead sponsor
- Philipps University of MarburgCollaborator
- Ludwig Maximilians UniversityCollaborator
- University of HamburgOverall official - principal investigator
- German Center for Infection ResearchCollaborator
- CTC Bio, Inc.Collaborator
- IDT BiologikaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.